Compare IDEXX Laboratories, Inc. (IDXX) vs M&T Bank Corporation (MTB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs M&T Bank Corporation — how do they compare? IDEXX Laboratories, Inc. trades at $572.2 (market cap $46.22B), while M&T Bank Corporation trades at $252.14 (market cap $36.42B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap, and M&T Bank Corporation pays a 2.38% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | MTB | |
|---|---|---|
Market Cap | $46.22B | $36.42B |
Sector | Health | Financials |
52-Week High | $766.68 | $254.04 |
52-Week Low | $526.44 | $178.63 |
Enterprise Value | $47.12B | — |
Dividend Yield | — | 2.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $595.76, up 1.55% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $4.27 versus $3.94 expected, driven by 9% organic revenue growth. The company raised full-year EPS guidance to $14.69–14.94, reflecting robust demand in companion animal diagnostics. Valuation ratios remain elevated with a P/E of 41.23, supported by high profitability margins including a net income margin of 25.03% and ROE of 74.21%.
Outlook is positive given consistent earnings beats, international expansion, and product innovation, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $683.33 implies 14.7% upside, with 57% of analysts rating it Buy. Investors should weigh growth durability against high multiples.
M&T Bank (MTB) trades at $251.13, up 0.27% on the day, with a bullish technical signal and strong recent earnings beats. The stock shows consistent revenue growth, with 2025 revenue at $9.63B and net income margin of 29.59%, supported by a P/E of 13.35. Analyst consensus is a Hold with a $255.92 price target, while recent news highlights robust Q2 2026 results and dividend stability.
Outlook remains positive due to earnings momentum and loan growth, but risks include rising costs and macroeconomic pressures. The stock offers value with a reasonable valuation and dividend yield, though investor caution is warranted amid mixed analyst ratings and net cash flow challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →
